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Key Points
• iNKT cells control CLL
progression in both mice and
patients and this inversely
correlates with CD1d
expression by leukemia
cells.
• Human iNKT cells indirectly
hinder CLL survival by
restraining proleukemia
monocyte-derived nurse-like
cells.
Chronic lymphocytic leukemia (CLL) ischaracterizedby theexpansionofmalignantCD51
B lymphocytes in blood, bone marrow, and lymphoid organs. CD1d-restricted invariant
natural killer T (iNKT) cells are innate-like T lymphocytes strongly implicated in tumor
surveillance.We investigated the impact of iNKT cells in the natural history of the disease
in the Em-Tcl1 (Tcl1) CLLmousemodel and 68CLL patients.We found that Tcl1-CLL cells
express CD1d and that iNKT cells critically delay disease onset but become functionally
impairedupondiseaseprogression. In patients, diseaseprogression correlateswithhigh
CD1d expression on CLL cells and impaired iNKT cells. Conversely, disease stability
correlates with negative or low CD1d expression on CLL cells and normal iNKT cells,
suggesting indirect leukemia control. iNKT cells indeed hinder CLL survival in vitro by
restraining CD1d-expressing nurse-like cells, a relevant proleukemia macrophage
population. Multivariable analysis identified iNKT cell frequency as an independent
predictor of disease progression. Together, these results support the contribution
of iNKT cells to CLL immune surveillance and highlight iNKT cell frequency as a
prognostic marker for disease progression. (Blood. 2017;129(26):3440-3451)
Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult
leukemia,1,2 characterized by the expansion ofmaturemalignantCD51
Bcells.3CLL is clinically heterogeneous, andpatients experience either
stable or progressive diseasewith accumulation of malignant B cells in
lymph nodes, spleen, bone marrow, and peripheral blood.4 Nurse-like
cells (NLCs) areCLL-specific tumor-associatedmacrophages (TAMs),
which can differentiate in vitro from monocytes cultured with CLL
cells.5 They sustainmalignantB-cell survival6,7 and are amajor cellular
component of the leukemiamicroenvironment in lymphoid tissues8,9 of
patients with progressive but not stable disease, suggesting that these
cells have an impact on the natural history of CLL.10,11
Type I invariant natural killer T (iNKT) cells are a conserved T-cell
subset expressing a semi-invariant T-cell receptor (TCR) containing the
Va14-Ja18 and Va24-Ja18 chains in mice and humans, respectively.
iNKT cells react with self- or microbial-derived lipid antigens, such as
a-galactosyl ceramide (a-GalCer), presentedby theHLAclass I–related
molecule CD1d. iNKT cells exhibit an innate-like effector phenotype
and swiftly respond to stimulation by upregulating costimulatory
molecules and cytokines, conferring on them a central role in tumor
immune surveillance.12 iNKT cells can control tumor growth either
by direct recognition of CD1d-expressing tumor cells, or indirectly,
by activation of antitumor CD81 T andNK cells or bymodulation of
protumor myelomonocytic cells.13-18 In cancer patients, decreased
iNKT cell numbers and interferon-g (IFN-g) production correlate
with adverse prognosis.19-21
In CLL patients, it was reported that CD1d expression bymalignant
cells correlates with adverse prognosis, whereas iNKT cells can
recognize leukemia cells in vitro when preloaded with synthetic
a-GalCer.22-24 However, the role of iNKT cells in the natural history
of CLL is essentially unknown.
Our study addresses this issue in Tcl1 mice, a widely accepted
mouse model of CLL,25 and in a cohort of 68 CLL patients. In mice,
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we found that iNKT cells controlled leukemia onset but became
functionally impaired upon disease progression. iNKT cells were
consistently deeply impaired in patients with disease progression, and
this somewhat unexpectedly correlates with high CD1d expression on
autologous CLL cells. By contrast, in patients with stable disease, CLL
cells display no or low CD1d expression, whereas iNKT cells retain
intact functions and can control leukemia cell survival in vitro by
restraining protumor functions of NLCs. iNKT cell frequency has
emerged as a new valuable prognostic factor for progressive leukemia.
Methods
Mice
C57BL/6N wild-type (wt) (Charles River Laboratories, Calco, Italy), Em-
TCL1,25 Ja182/2,26 and CD1d2/2 mice27 (all on the C57BL/6N background)
were treated in accordance with the Institutional Animal Care and Use
Committee of SanRaffaele Scientific Institute,Milan, Italy. Em-Tcl1micewere
crossed with Ja182/2 or CD1d2/2mice to obtain Tcl1-Ja182/2 or Tcl1-CD1d2/2
mice.
Patients
CLL diagnosis, prognostic factors, and disease progression (Table 1) were
documented according to the International Workshop on CLL 2008 criteria
(IWCLL 2008).28 All patients were either untreated or off therapy for at least
6months (range, 6 to 12months) before the beginning of the study. Patientswith
progressive disease who were receiving antileukemia treatment were excluded
from the study. Progressive disease was defined per IWCLL 2008 criteria and
was based on the presence of at least 1 of the following clinical parameters:
anemia and/or thrombocytopenia as a result of bone marrow infiltration by
CLL, bulky symptomatic or progressive lymph nodes, massive symptomatic
or progressive splenomegaly, uncontrolled autoimmune anemia and/or
thrombocytopenia, lymphocyte doubling time,6 months, and/or B symptoms
(drenching night sweats, fever, unexplained weight loss). Peripheral blood from
CLL patients and age-matched healthy donors and lymph node samples from
CLL patients were obtained after patients provided written informed consent in
accordance with the Declaration of Helsinki.
Mouse cells and tissues
iNKT cells were expanded in vitro for 14 days from total splenocytes of wt mice
with 100 ng/mL a-GalCer (Kyowa Hakko Kirin, Tokyo, Japan), 40 U/mL
recombinant human interleukin-2 (rhIL-2) (Novartis, Basel, Switzerland), and
10 ng/mL recombinantmouse IL-7 (rmIL-7) (R&DSystems,Minneapolis,MN).
To obtain dendritic cells (DCs), bone marrow cells from wt mice were cultured
for 5 days with 25 ng/mL granulocyte-macrophage colony-stimulating factor
plus 5 ng/mL IL-4 (R&D Systems) and enriched with mouse CD11c beads
(Miltenyi Biotec, Bergisch Gladbach, Germany). CLL cells were isolated with
a mouse B-cell enrichment kit (EasySep, STEMCELL Technologies) from
Tcl1 and Tcl1-CD1d2/2 mice. DCs and CLL cells were loaded in vitro with
200 ng/mL a-GalCer. Tcl1 tissues were paraffin included, sectioned, and
stained with hematoxylin and eosin.
Human cells
iNKT cells were expanded and purified from healthy donor–derived peripheral
blood mononuclear cells (PBMCs) with 100 ng/mL a-GalCer as described.29
CLL cells, healthy donor B cells, and monocytes were purified from PBMCs
with a B/CLL isolation kit or anti-CD14 beads (Miltenyi Biotec), respectively.
T and CLL cells were depleted with anti-CD3 or anti-CD19 beads, respectively
(Miltenyi Biotec).
Flow cytometry
Antibodies were from BioLegend (San Diego, CA) unless otherwise noted.
Mouse CLL cells were stained with anti-CD19, anti-immunoglobulin M (anti-
IgM), anti-B220, and anti-CD1d monoclonal antibodies (mAbs); mouse
iNKT cells were stained with anti-TCRb mAb and PBS57-loaded mouse
CD1d (mCD1d) tetramers (obtained from the National Institutes of Health
Tetramer Core Facility). Human cells were analyzed in whole blood: CLL cells
were stained with anti-CD5, anti-CD19, and anti-CD1d (BD Biosciences, San
Jose,CA) or unlabeled anti-CD1d and goat anti-mouse IgGAbs (ThermoFisher,
Waltham, MA), iNKT cells were stained with anti-CD3 or anti-TCRa/b (BD
Biosciences), anti-Va24, anti-Vb11 (Coulter, Brea, CA) or anti-Va24-Ja18
(Miltenyi Biotec), anti-CD4, and anti-CD127 mAbs (Coulter). Human
monocytes were stained with anti-CD14 and anti-CD1d. Intracellular cytokine
production by iNKT and T cells was determined by using anti-IFN-g mAbs.
Samples were acquired on a FACSCanto II flow cytometer or an LSRFortessa
X-20 analyzer (BD Biosciences), excluding dead cells and doublets, and
analyzed with FlowJo 10.0.6 software.
iNKT cell activation assays
Murine iNKT cells were activated in vivo by intravenous injection into mouse
a-GalCer preloaded DCs, and serum IFN-g was measured by using enzyme-
linked immunosorbent assay (ELISA).Murine iNKTcellswere activated in vitro
by culturing themwith a-GalCer loaded or unloaded CLL cells at a 2:1 effector:
target (E:T) ratio with or without 10 mg/mL anti-CD1d blocking mAb (clone
1B1; BioLegend).30 Secreted IFN-g was tested after 48 hours by ELISA. To
activate primary human iNKT cells from CLL patients, PBMCs were depleted
from CLL cells and incubated with anti-CD3/anti-CD28 beads (Life
Technologies/Invitrogen) (1:1 T cell:bead) or phorbolmyristate acetate (PMA;
25 ng/mL) plus ionomycin (1 mg/mL) (Sigma). After 16 hours, 10 mg/mL
BrefeldinA (Sigma)was added for 2 hours before intracellular cytokine staining.
To activate healthy iNKT cell lines in vitro, freshly isolated healthy B or CLL
cells were cultured at the indicated numbers with 2 3 104 iNKT cells with
or without 20 mg/mL blocking anti-CD1d (clone 51.1; BioLegend).31 After
48 hours, secreted IFN-g was determined by ELISA.
Culture and imaging of NLCs
Frozen lymph node sections were stained with anti-CD68 (Abcam, Ltd.,
Cambridge, UK) and anti-CD1d (clone 42.1; BD Biosciences) mAbs, followed
by labeled goat anti-rabbit and goat anti-mouse Abs (Thermo Fisher),
respectively, and 49,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher) for
nuclei counterstaining. NLCs were differentiated in vitro from patient-derived
T-cell–depleted PBMCs,6,7 and after 7 to 10 days, they were stained with anti-
CD1d mAbs followed by goat anti-mouse Ab heavy and light chains (H&L)
Table 1. Patient characteristics
Characteristic
No. of patients/total
patients %
Patient parameters
Total no. of patients 68
Median age at diagnosis (range), y 67 (41-89)
Male sex 39
Clinical parameters
Rai stage at diagnosis
0 42/60 70
1-4 18/60 30
IGHV mutational status
Mutated 37/58 63.8
Unmutated 21/58 36.2
CD38 expression, %
,30 53/65 81.5
.30 12/65 18.5
ZAP-70 expression, %
,20 34/59 57.6
.20 25/59 42.4
Chromosomal aberrations
Trisomy 12 7/63 11.1
FISH del11q 10/63 15.9
FISH del17p 11/63 17.4
FISH, fluorescent in situ hybridization.
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Figure 1. Lack of NKT cells in Tcl1 mice accelerates leukemia onset and progression. (A) Representative flow cytometry analysis of normal (IgM1B220high) and
malignant (IgM1B220low) CD191 B cells from the blood of the indicated mouse strains at 30 weeks of age and CD1d expression on healthy and malignant B cells in Tcl1 mice
at 15 and 45 weeks of age. (B) Longitudinal analysis of leukemia progression in peripheral blood (n 5 16 mice per group). Temporal average kinetic curves describing
malignant B-cell frequency as a function of age (50-week range) were calculated for each mouse group (thick colored lines) by mixed-effect model analysis. Age of mice at
which CLL frequency reaches 50% of the asymptotic value is 28.5 weeks for Tcl1-CD1d2/2, 30.6 weeks for Tcl1-Ja182/2, and 34.1 weeks for Tcl1 mice. Student t test: Tcl1-
CD1d2/2 vs Tcl1-Ja182/2 mice, P5 .0084; Tcl1-Ja182/2 vs Tcl1 mice, P 5 .00018. Thin gray curves smoothed via local regression with Gaussian kernel describe the kinetic
(30-week) range of malignancy expansion for each animal; the average kinetics (thick colored lines) are superimposed for each strain. (C) CLL disease score of hematoxylin
and eosin (H&E)–stained tissue sections from different organs from Tcl1 and Tcl1-Ja182/2 mice at different ages as indicated, defined by a pathologist in a blinded fashion on
the basis of the degree of leukemia infiltration and disruption of the normal organ architecture in spleen (SPL), liver (LV), kidney (KD), lung (LG), lymph node (LN), and bone
marrow (BM). Box plots depict first quartile, median, and third quartile. The outlier values (circles) less than interquartile range (IQR) –1.5 or greater than IQR11.5 are shown.
Vertical bars represent whiskers indicating the distance from the smallest (lower bar) and the highest (upper bar) nonoutlier values from the first and third quartile, respectively.
*P , .05 Wilcoxon test. (D) H&E staining of tissue sections from spleens of 1 representative Tcl1 (left panel) and Tcl1-Ja182/2 (right panel) mouse at 17 weeks of age. The
splenic architecture of red pulp (RP) in the Tcl1 mouse is maintained, whereas it is substituted by CLL cells in Tcl1-Ja182/2 mice (original magnification 340). Images were
acquired with Zeiss AxioImager M2m equipped with Nuance FX Multispectral Tissue Imaging System and Nuance Acquisition Software. (E) Tcl1 and wt mice at 20 and
50 weeks of age received a-GalCer–loaded DCs intravenously, and IFN-g serum level was measured by ELISA at the indicated times. Each curve represents the IFN-g
released by each mouse. One representative result of 3 independent and consistent experiments is shown. **P # .005 Wilcoxon test. (F) Purified CLL from Tcl1 and
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(Thermo Fisher) and were fixed and examined by either immunofluorescence or
by confocal microscopy upon nuclear counterstaining with DAPI. Purified
donor-derived monocytes, allogeneic donor-derived iNKT cells, and purified
CD1dneg CLL cells were co-cultured (at a 1:3:5 ratio, respectively) with or
without 20 mg/mL anti-CD1d blocking mAb for 7 to 10 days, with 10 U/mL
rhIL-2 (Novartis) added only at day 1. T-cell–depleted patient-derived PBMCs
were cultured for 14 days with or without allogeneic donor–derived iNKT cells
(1:3 iNKT cell to monocyte ratio). Surviving CLL cells were removed from the
cultures and counted by Flow-Count Fluorospheres (Coulter). Adherent cells
remaining in the cultures were either counted after nuclei labeling with Hoechst
stain (Thermo Fisher) or stained with anti-CD68 mAb (BD Biosciences) and
DAPI for immunofluorescence and quantitative image analysis. Brightness and
contrast were optimized for visualization with ImageJ software.
Statistics
Malignant B-cell expansion kinetics in Tcl1 mice were compared by using
nonlinear mixed-effects models32 as reported.21 Differences between groups
were assessed by 2-sided (unless otherwise noted) unpaired Student t test or
Wilcoxon test for non-Gaussian distributions. Linear correlation between
2 parameter categories was evaluated by Spearman’s test. For multiple group
comparisons, 1-way analysis of variance was adopted. A P value , .05 was
considered statistically significant. For multivariable analysis of human CLL
prognostic factors, a generalized linear model (GLM)33,34 was fitted on the data
(see supplemental Data, available on the BloodWeb site) using R language and
environment for statistical computing.35
Results
iNKT cells control leukemia onset and initial organ infiltration in
Tcl1 mice
We investigated the surveillance of CLL cells by iNKT cells in the
transgenic leukemia Tcl1 mouse model,25 in which malignant CD191
CD51IgM1B220low B cells progressively expand from 8weeks of age
(Figure 1A).36 Leukemia cells from Tcl1 mice expressed CD1d at
constant levels during disease progression, similar to the normal B-cell
counterpart (Figure 1A). Tcl1 mice were crossed with Ja182/2 (Tcl1-
Ja182/2) or with CD1d2/2 (Tcl1-CD1d2/2) mice lacking iNKT cells
and all CD1d-restricted NK T cells, respectively.17 A longitudinal
analysis of CLLperipheral expansion estimated that the leukemia onset
and progressionwere significantly faster in NKT-cell–deficient than in
NK T-cell–sufficient Tcl1 mice up to 30 weeks of age (Figure 1B).
At later disease stages, the 3 mouse strains exhibited similar rates of
CLL progression and by 50 to 55 weeks, they developed full-blown
leukemia (Figure 1B) with similar overall survival (data not shown).
Histopathology analysis revealed a more aggressive disease infiltration
of spleen and lymph nodes in 16- to 17-week-old Tcl1-Ja182/2mice
compared with Tcl1 mice (Figure 1C-D). Conversely, 39- to 43-week-
old Tcl1 and Tcl1-Ja182/2 mice exhibited comparable leukemia
infiltration scores (Figure 1C-D). To assess the functionality of iNKT
cells upondisease progression,we injecteda-GalCer preloadedwtDCs
in 20- and 50-week-old Tcl1 and wt mice and assessed serum IFN-g
production up to 24 hours later. The cytokine concentration was
comparable in 20-week-old Tcl1 andwtmice (Figure 1E). However, at
50 weeks, and irrespective of similar numbers of splenic and liver
iNKT cells in leukemic and healthy animals (supplemental Figure 1),
IFN-g production from Tcl1 mice was markedly impaired (Figure 1E),
suggesting the acquisition of functional defects by autologous iNKT
cells. We then investigated whether normal iNKT cells could directly
recognize CD1d-expressing CLL cells in vitro. iNKT cells were
directly activated by purified CLL cells from Tcl1 mice but not wt
B cells, suggesting the recognition of CD1d-restricted endogenous
leukemia-derived lipids. Preloading healthy or leukemia B cells with
a-GalCer resulted in robust iNKT cell activation, confirming that both
cell typeswere capable of presenting lipid antigens (Figure 1F). Finally,
we investigated whether CD1d expression on CLL cells was a
prerequisite for leukemia surveillance by iNKT cells. Purified CLL
cells from Tcl1 or Tcl1-CD1d2/2mice were loaded or not loaded with
a-GalCer in vitro and then injected into wt animals. The progression
of both a-GalCer preloaded CD1d1/1 or CD1d2/2 CLL was signifi-
cantly delayed in blood and spleen compared with unloaded cells
(Figure 1G-H), indicating that CD1d expression on CLL was
dispensable for leukemia surveillance by iNKT cells.
Collectively, these results suggested that iNKT cells controlled
the initial CLL expansion phase by mechanisms that may not require
direct leukemia cell recognition but became functionally impaired upon
disease progression.
High CD1d expression on CLL cells and iNKT cell impairment
correlate with disease progression in patients
The above results prompted us to search for a clinical correlate of
iNKT cell immune surveillance in a cohort of 68 CLL patients
(Table 1). CD1d was expressed on CD191CD51 CLL cells with an
intrapatient unimodal profile but variable interpatient intensity
(Figure 2A). In 46 patients, we determined the circulating iNKT cell
frequency (range, 0% to 0.35% of total T cells; median, 0.0235%) and
absolute numbers (0 to 0.0056 cells per mL of blood; median, 0.0005
cells per mL of blood). These patients displayed a significant inverse
correlation between the level of CD1d expression on CLL cells and the
autologous iNKT cell frequencies and counts (Figure 2B). Importantly,
CD1d expression on CLL cells was significantly higher and iNKT
cell frequency and number were significantly lower in patients with
progressive disease than in patients with stable disease (Figure 2Ci,iii,
iv). The differential CD1d expression between patientswith progressive
disease and patients with stable disease was specific for the malignant
but not the normal autologous B-cell compartment, which instead
expressed comparable (and significantly higher than malignant cells;
P, .05)CD1d levels in both stable andprogressive cohorts (Figure 2Cii).
We next assessed whether the residual circulating iNKT cells in
patients with progressive disease were also functionally impaired, as
observed in Tcl1 mice with advanced disease. Indeed, iNKT cells
from CD1dhigh (relative fluorescence intensity [RFI] $3) patients did
not respond to activation by either a-CD3/a-CD28 beads or PMA/
ionomycin (Figure 2D), whereas autologous T cells displayed selective
unresponsiveness only upon activation by a-CD3/a-CD28 beads but
not PMA/ionomycin, as reported.37 By contrast, iNKTandTcellswere
Figure 1 (continued) Tcl1-CD1d2/2 mice and purified B cells from wt mice preloaded or not with a-GalCer were cultured for 48 hours with iNKT cell lines from wt mice with or
without anti-CD1d blocking mAb as indicated, and the released IFN-g was measured by ELISA. Graphs depict mean 6 standard deviation (SD). One representative result of
2 independent and consistent experiments is shown. *P, .05; **P# .005; ***P# .0005; ****P# .00005 1-way analysis of variance (ANOVA). (G) In all, 23 106 purified and a-GalCer
preloaded CLL cells from Tcl1 or Tcl1 CD1d2/2mice were injected intraperitoneally into C57BL/6Nmice (n5 6 per group). The expansion of circulating CLL cells was monitored by flow
cytometry at the indicated time points. One of 2 comparable independent experiments is shown. Graphs depict mean values (symbols) 6 SD. *P , .05; **P # .005 Wilcoxon test. (H)
Posttransplant spleen infiltration by CLL cells. The number of spleen-infiltrating CD191IgM1B220low cells from Tcl1 mice was compared 50 days posttransplantation (shown in [G]) with
a-GalCer preloaded (a-GalCer) and unloaded (UnL) Tcl1 CLL cells; healthy wt mice were used as control. Bars indicate means 6 SD. **P # .005, ***P # .0005; 1-way ANOVA.
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Figure 2. High CD1d expression on CLL cells and defective iNKT cells correlate with disease progression in patients. (A) Representative flow cytometry detection of
CD1d expression on CD191CD51 CLL cells and of iNKT cells in total TCRa/b T cells from 1 patient with stable disease (upper panel) and 1 patient with progressive disease
(lower panel). (B) Statistically significant inverse correlation between CD1d expression on CLL cells and autologous iNKT cell frequency (left panel, P 5 .002551) or iNKT cell
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both fully functional in patientswith CD1dneg/low (RFI,3) CLL stable
diseaseor healthy donors.BothCD41andCD4– iNKTcell subsets38,39
from patients with CD1dhigh CLL produced less IFN-g and IL-13 upon
ex vivo stimulation compared with the cells from patients with
CD1dneg/low CLL and healthy age-matched participants (Figure 2D-E;
data not shown). IFN-g production by iNKT cells inversely correlated
withCD1d expression (Figure 2F) unlike T cells, suggesting a selective
CD1d-related functional impairment of iNKT cells.
Thus, disease progression correlated with CD1d expression by
malignant cells and defective iNKT cell counts and functions in CLL
patients, akin to that in Tcl1 mice, suggesting an active participation of
iNKT cells in leukemia surveillance.
CD1d molecules expressed by CLL cells stimulate normal
iNKT cells
We reasoned that the iNKT cell functional and numerical attrition in
CD1dhigh CLLpatientsmight result from 2 alternativemechanisms: (1)
a persistentCD1d-dependent stimulationbyCLLcells, similar to that in
T cells during chronic viral infection or malignancies40,41; or (2) a
A
HD B cells
CLL cells 
ctrl
CLL 19 CLL 46CLL 30 CLL 56
B
CLL cells 
CLL cells + -CD1d
HD B cells
HD B cells + -CD1d 
CD1d
C
D
0
20
40
60
80
100
Stable CLL
CD1dNeg/Low
Progressive CLL
CD1dHigh
T cellsiNKT cells
CD
12
7
CD4
52 42
6 0
23 55
19 2
19 50
14 17
31 29
33 6
CD
12
7 
(R
FI
)
iNKT cells T cells
Stable CLL 
CD1dNeg/Low
Progressive CLL 
CD1dHigh
***
***
CLL cell number (x103) 
0
0.1
0.2
0.3
0.4
200 60 20
0
2
4
6
8
10
200 60 20
***
IF
N-
 (
ng
/m
l)
0
10
20
30
40
50
200 60 20
***
***
0
15
200 60 20600
10
5
*** ***
***
Figure 3. Differential recognition of CLL and healthy B cells by iNKT cells. (A) CD1d expression by flow cytometry in primary CLL cells and B cells from 4 patients and
4 healthy donors, respectively, used in pairs for iNKT cell activation. (B) The same paired cells were cultured for 48 hours at the indicated numbers with 2 3 104 iNKT cells
from healthy donors with or without anti-CD1d (a-CD1d) mAb. IFN-g release by iNKT cells was measured by ELISA and expressed as mean 6 SD. (C) Ex vivo CD127
expression determined by flow cytometry in patients with CD1dneg/low stable CLL vs patients with CD1dhigh progressive CLL. The percentage of CD127-expressing iNKT and
T cells is indicated. (D) Frequency of CD127 iNKT and T cells from patients with stable or progressive disease. Graph symbols show single individual values 6 SD. ***P , .0005
1-way ANOVA.
Figure 2 (continued) number (right panel, P 5 .005213 Spearman’s correlation test). Scatter plot graphs show single patient value (symbols) with superimposed lines
representing the estimated linear regression models (46 patients). (C) Shown are the (i) association of a high CD1d expression on CD191CD51 CLL cells (n 5 68 patients)
with CLL progression, (ii) the absence of significant difference between CD1d expression on nonmalignant CD191CD5– cells in patients with stable or progressive disease
(same cohorts as in [i]), (iii) the correlation between iNKT cell frequency (n 5 50 patients), and (iv) number of patients (n 5 46) with CLL progression. Box plots depict first
quartile, median, third quartile, outliers (circles), and whiskers proportional to IQR. *P , .05; **P , .005; 1-sided Wilcoxon test. (D) Intracellular staining flow cytometry
analysis of IFN-g production by primary circulating iNKT cells from a representative age-matched healthy donor, a CD1dneg/low CLL patient, and a CD1dhigh CLL patient upon
ex vivo activation with anti-CD3/anti-CD28 beads or PMA/ionomycin. The percentage of IFN-g–producing iNKT and T cells is indicated. (E) Frequency of IFN-g–producing
CD41 (filled circle) and CD4– (empty circle) iNKT cells from age-matched healthy donors, CD1dneg/low CLL patients, and CD1dhigh CLL patients upon a-CD3/a-CD28 bead
activation. Graph symbols show single individual values 6 SD. *P , .05 Wilcoxon test. (F) Correlation between CD1d expression on CLL cells and the frequency of
IFN-g–producing iNKT cells and T cells upon a-CD3/a-CD28 bead activation. Scatter plot graphs show single patient (n 5 15) values for iNKT and T cells (circles) with
superimposed lines representing the estimated linear regression models for iNKT cells (solid) and T cells (dashed). Shown is a significant negative correlation between CD1d
expression on CLL cells and frequency of IFN-g–producing iNKT cells (P 5 .0096) but not T cells (P 5 .1136; Spearman’s correlation test).
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defective CD1d-dependent stimulation by CLL cells resulting from
dysfunctional antigen-presenting functions ofmalignant B cells.17,42-44
To address these issues, we cultured iNKT cell lines from healthy
donors with purified CD1dneg/low or CD1dhigh CLL cells, or B cells
from healthy donors with or without anti-CD1d blocking antibody.
IFN-g was secreted in a CD1d-dependent manner by iNKT cells upon
direct recognition of 3 of 4 CD1dhigh but none of 4 CD1dneg/low CLL
cells (Figure 3A-B; data not shown). Notably, iNKT cells were more
efficiently activatedbymalignantBcells thanbynormalBcells,despite
similar levels of CD1d expression. The results showed that CLL cells
expressing CD1d were able to strongly stimulate iNKT cells in vitro
without the addition of a-GalCer, possibly leading to their progressive
exhaustion in vivo. Consistent with an exhausted state,41 primary
iNKT cells from patients with progressive disease displayed (in ad-
dition to the functional unresponsiveness showed above; Figure 2 D-F)
a lower IL-7 receptora chain (CD127) expression comparedwith cells
from patients with stable disease (Figure 3C-D). The reduced CD127
expression was significant for iNKT but not for autologous T cells
(Figure 3C-D), further suggesting that iNKT cells might undergo a
selective exhaustion process in patients with aggressive CLL.
iNKT cells indirectly impair CLL cell survival by restraining
proleukemia NLCs in vitro
The results obtained above implied that iNKT cells could hinder the
progression ofCD1d–CLL, raising the question of how thismay occur.
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Figure 4. Monocytes and NLCs from CLL patients express CD1d. (A-B) CD1d expression by NLCs in vivo. Frozen lymph node sections from 2 patients with progressive
CLL co-stained with anti-CD1d mAb plus goat anti-mouse fluorescein isothiocyanate (FITC) (green), anti-CD68 mAb plus goat anti-rabbit phycoerythrin (PE) (red) Abs, and DAPI
(blue). Macrophages co-expressing CD1d and CD68 (yellow arrows) are detectable scattered within (A) dense macrophage infiltrates (original magnification 3400) or in (B)
macrophage clusters (original magnification 3200), surrounded by lymphoid elements compatible with CLL cell morphology. Sections were analyzed with a Zeiss AXIO Scope.A1
optical microscope (Zeiss, Oberkochen, Germany). Images were collected with Zeiss Axiocam 503 Color. (C) Representative CD1d expression detected by flow cytometry in
circulating monocytes from 1 of 10 CD1dneg CLL patients. (D) CD1d expression by NLCs differentiated in vitro from patients’ PBMCs. Adherent cells were stained with anti-CD1d
mAb plus goat anti-mouse PE (green) and DAPI (blue). (Left panel) CD1d expression by immunofluorescence analysis in 1 representative field (original magnification320) of 20 to
40 fields per patient performed on 6 patients. (Middle panel) Bright field (gray) merged with CD1d immunofluorescence and DAPI nuclei staining (original magnification 320)
showing NLCs with typical stellate morphology. Immunofluorescence was performed by In Cell Analyzer 1000 GE Healthcare and In Cell Analyzer 1000 Workstation or Arrayscan
XTI (Thermo Fisher) with HCS studio software. (Right panel) The same NLCs were stained with anti-CD1d PE mAb and DAPI for confocal imaging. CD1d is localized on the cell
surface and in punctate structures (original magnification 363). Confocal imaging was performed with Confocal Microscope Leica TCS SP2.
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We hypothesized that iNKT cells might indirectly control leukemia
progression by restraining NLCs, which are reported to be CLL-
specificTAMsendowedwith proleukemia functions.5-7 To address this
issue,wefirst verified the expression ofCD1dbyNLCs in vivo. Lymph
node sections from 2 patients with progressive CLL contained large
CD681 stellate cells that displayed a macrophage-like morphology
compatible with that of NLCs that co-expressed CD1d at variable
intensity (Figure 4A-B). Immunohistochemistry staining of lymph
node sections from a third patient with progressive CLL confirmed the
presence of scattered CD1d1 macrophage-like cells surrounded by
packed elements that displayed CLL cell morphology (supplemental
Figure 2). Irrespective of CD1d expression by autologous CLL cells,
CD1d was also expressed by primary monocytes (isolated from
patients) that were considered NLC precursors (Figure 4C), as well as
by NLCs spontaneously differentiated in vitro upon culturing
T-cell–depleted PBMCs from CLL patients (Figure 4D). Second, we
investigated the effects of iNKT cells on the differentiation of healthy-
donor monocytes into NLCs upon coculture in vitro with purified CLL
cells, as described.6,7 CD141monocytes were cultured in the presence
or absence of allogeneic purifiedCD1dnegCLL cells and healthy-donor
iNKT cells. We used this source of iNKT cells to overcome the
quantitative limitations of the clinical samples, assuming that theywere
functionally comparable with the cells from patients with CD1dneg/low
CLL stable disease. After 7 days of culture (Figure 5A), iNKT cells
markedly reduced the number of adherent NLCs, which were
significantly restored in the presence of anti-CD1dmAbs. Consistent
with the absence of CD1d expression on CLL cells, iNKT cells did
not directly impair their survival, which was actually sustained by
coculture with monocytes (Figure 5A).6
Third, we assessed whether iNKT cells could affect the
differentiation of patient-derived NLCs in vitro and, in turn, the
survival of CD1dneg CLL cells. T-cell–depleted PBMCs fromCD1dneg
CLL patients were cultured in the presence or absence of iNKT cell
lines from healthy donors. After 14 days of coculture, NLC and CLL
counts were markedly reduced in the presence of iNKT cells
(Figure 5B,D,F). Furthermore, the adherent cells, differentiated in the
absence of iNKT cells, exhibited a macrophage-like shape and
homogeneous intracellular CD68 expression typical of NLCs
(Figure 5B,C,E). By contrast, the residual adherent cells differentiated
in the presence of iNKT cells were mostly spindle shaped and nega-
tive for CD68 expression (Figure 5B,C,E). Collectively, these results
suggested that iNKT cells can indirectly impair CLL viability by
restraining NLC differentiation in a CD1d-depedent manner.
iNKT cell percentage predicts CLL progression in
multivariable analysis
In light of the correlation between high CD1d expression by CLL cells
and low iNKT cell frequency with disease progression, we compared
the prognostic value of these 2 parameters with the currently used
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Figure 5. iNKT cells control CLL survival by restraining proleukemia functions of NLCs. (A) iNKT cells impair NLC generation in vitro. Shown is the number of adherent
NLCs differentiated from CD141 monocytes of healthy donors upon culturing in vitro for 7 days with or without purified CD1dneg CLL cells, healthy iNKT cells, anti-CD1d
blocking mAb. (Left panel) Quantitative image analyses of 60 different fields were taken from each well. (Right panel) CLL cells cultured with or without iNKT cells or
monocytes were collected and counted by flow cytometry in duplicates. Results are expressed as mean 6 SD and are represent 1 of 3 consistent experiments. **P # .005;
***P # .0005 1-way ANOVA. (B-F) iNKT cells impair CLL and NLC survival in vitro. T-cell–depleted PBMCs from a CD1dneg CLL patient were cultured in vitro with or without
purified healthy iNKT cells. After 14 days of culture, CLL cells were collected and adherent cells were assessed for morphology in (B) bright field (original magnification 320)
and (C) stained with CD68-FITC (green) and DAPI (blue) for immunofluorescence (original magnification 320). Quantitative image analyses of 20 different fields were taken
directly from the same culture wells to determine (D) total adherent cell counts and (E) CD681 adherent cell counts. (F) The CLL cells that were harvested from the same wells
were counted by flow cytometry in quadruplicate. Bars show mean6 SD. Data refer to 1 of 2 independent experiments performed with different patients that gave comparable
results.*P , .05; ****P # .00005 Wilcoxon test. Immunofluorescence and counts were performed by In Cell Analyzer 1000 GE Healthcare and In Cell Analyzer 1000
Workstation or Arrayscan XTI (Thermo Fisher) with HCS studio software. Bright field image acquisitions were performed with Zeiss Axio Observer.z1 with QImaging EXI-Blue
equipped with Velocity acquisition software.
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markers: Rai clinical stage, ZAP-70 and CD38 expression, chromo-
somal aberrations, and IGHV gene mutational state of CLL cells. The
univariable statistical analysis of our cohort of patients showed that, as
expected, disease progression was associated with higher numbers of
different chromosomal aberrations, CD38 expression, and unmutated
IGHV genes and also with lower iNKT cell frequencies and higher
CD1d expression on CLL cells than in stable disease (Table 2;
Figure2C).Topredict the progressionprobability, the aboveprognostic
factors were included as covariates of a GLM in a multivariable
analysis. In the GLM-1 model containing all markers, a backward
stepwise analysis (supplemental Table 1) selected iNKT cell frequency
and CD38 expression on CLL cells as the best significant independent
prognostic factors (Spearman correlation test between the 2 covariates,
P5 .85) (Table 3).A secondGLM(GLM-2) (Table 3)was generated on
the basis of only the classical CLL prognostic factors, excluding
iNKT cell frequency and CD1d expression on CLL cells. By using this
procedure, CD38 expression was selected as a unique significant CLL
prognostic factor. However, GLM-1 predicted the progression probabil-
ityofpatientswithhigher sensitivity thanGLM-2 (supplementalTable2),
highlighting iNKT cells as a potential novel CLL prognostic parameter.
Discussion
Our results provide compelling evidence for the involvement of
iNKT cells in the immune surveillance against CLL in both mouse
models and patients. Indeed, the absence of iNKT cells in Tcl1 mice, a
realistic preclinical model of human CLL, accelerated the leukemia
onset and initial infiltration (before 30 weeks of age) in secondary
lymphoid tissues.Mechanistically, our study suggested that iNKT cells
might control CLL cells independent of direct recognition. Moreover,
leukemia expanded earlier in Tcl1-CD1d2/2 mice that lacked iNKT
type I and type II NKT cells compared with Tcl1-Ja182/2 mice that
lacked only iNKT cells, which suggests that, at least in CLL, type II
NKT cells may also display antitumor functions.17,45 This differs from
the immunosuppressive protumor role attributed to type II NKT cells in
some solid tumors.17,45 Consistent with previous reports,22,24,46 our
data showed CD1d expression on CLL cells from patients, although it
was distributed over awide range of intensity.We found that iNKT cell
counts and the expression level of CD1d on CLL cells were inversely
correlated. Patientswith lower numbers of iNKTcells had higherCD1d
expression on CLL cells and were more prone to disease progression,
whereas higher numbers of iNKT cell were associated with lower
or negative CD1d expression on CLL cells and disease stability.
Unexpectedly, lack of CD1d expression by malignant B cells did not
represent a mechanism of CLL evasion from iNKT cell surveillance,
in sharp contrast with the loss of major histocompatibility complex
expression by solid and hematologic tumors escaping from T-cell–
dependent selective pressure.47,48
Progressive dysfunctions of iNKT cells were similar in the Tcl1
model and inpatients, andbothwere associatedwith themaintenanceof
CD1d expression by CLL cells. The functional defect in Tcl1 mice is
intrinsic to iNKT cells because it could not be reversed in vivo by
activation with wt DCs preloaded with the potent agonist a-GalCer.
Moreover, the impaired IFN-g production by iNKT cells from patients
with CD1dhigh CLL and increased probability of progression is con-
sistent with the functional defect previously described in iNKT cells
fromcancer patientswith poor prognosis.19,20,49 This conditionwas not
described in CLL, possibly because patients were not previously
classified depending on either clinical stage (ie, stable or progressive
disease) or CD1d expression level on CLL cells.23 Significant
immunologic defects have been documented in CLL.42,50-52 In
particular, T cells from patients are hyporesponsive to a-CD3/CD28
triggering, whereas they produce more cytokines than healthy T cells
upon PMA/ionomycin activation.37,53 By contrast, iNKT cells from
patients with progressive CLL disease did not respond to either
anti-CD3/CD28 or to PMA/ionomycin activation, suggesting the
acquisition of distinct, more profound defects compared with
T cells. Moreover, iNKT cell, but not T-cell, responsiveness inversely
correlated with CD1d levels on CLL cells, indicating that iNKT cell
dysfunctions might derive from a CD1d-cognate contact with CLL
cells. In this respect,we indeed showed that in the absence ofa-GalCer,
primary CLL cells from Tcl1 mice, but not wt B cells, stimulated
iNKT cells in vitro in a CD1d-cognate manner. Furthermore, primary
human CD1dhigh CLL cells, but not healthy B cells, potently activated
Table 3. Multivariable analysis defines iNKT cell frequency and
CD38 expression on CLL as the best factors to predict CLL
progression probability
Model Parameter estimate SE P*
GLM-1
Intercept 0.23970 0.56097 .6692
iNKT cell frequency† 28.43884 3.33224 .0113
CD38‡ 0.02839 0.01272 .0256
GLM-2
Intercept 21.284757 0.340107 .000158
CD38‡ 0.028270 0.009687 .003519
The equation of GLM and the interpretation of parameter and intercept are
described in supplemental Data. Best GLM was generated by backward stepwise
selection (supplemental Table 1), including all the variables examined by univariable
analyses in Table 2. GLM-2 was generated by backward stepwise selection (detailed
in supplemental Table 1) by excluding iNKT cell frequency.
SE, standard error.
*P , .05 indicates factors with statistically significant prognostic contribution, as
calculated by backward stepwise selection, detailed in supplemental Table 1.
P values were obtained by means of 2-tailed Z test performed by using R software.
†iNKT cell frequency: selected prognostic factor; square root transformation was
adopted for iNKT cell frequency to account for the small positive values of iNKT cell
frequencies among total T cells.
‡CD38 expression on CLL is a selected prognostic factor.
Table 2. Univariable analysis defines the prognostic values for CLL
of currently used biomarkers, iNKT cells, and CD1d expression
Prognostic factor No. of patients tested P* Ordering†
Rai at diagnosis 60 .157 P.S
ZAP-70‡ 59 .097 P.S
Chromosomal aberration score‡§ 63 .034 P.S
FISH del 17p .243 P.S
Trisomy 12 .090 P.S
FISH del 11q .083 P.S
iNKT cell counts‡ 48 .050 P,S
CD1d expression‡ 64 .032 P.S
IGHV unmutated status 58 .003 P.S
iNKT cell frequency‡ 50 .003 P,S
CD38‡ 65 .0001 P.S
The distribution of each prognostic factor in patients with stable disease (S) vs
progressive disease (P) was compared by Wilcoxon tests.
FISH, fluorescent in situ hybridization.
*P values , .05 indicate statistically significant difference between patients with
progressive disease and those with stable disease.
†P.S tested the hypothesis with prognostic factor values higher among patients
with progressive disease than among patients with stable disease; P,S tested the
hypothesis with prognostic factor values lower among patients with progressive
disease than among patients with stable disease.
‡Each variable was evaluated as continuous.
§Chromosomal aberration score was calculated as the sum of total chromo-
somal aberration numbers per patient.
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iNKT cells without the addition of a-GalCer. These findings suggest
that iNKT cells can directly recognize leukemia-derived lipids
presented by CD1d on CLL cells. As a result of this, our findings
also support the hypothesis that iNKT cells might become functionally
exhausted upon chronic stimulation by CD1d-expressing CLL cells.
We indeed found a reduced CD127 expression by iNKT cells in
CD1dhigh progressive CLL, similar to the phenotype acquired by
exhausted T cells in the course of chronic viral infections.41 Because
IL-7 signaling via CD127 is critical for iNKT cell homeostasis,54,55
its decline might account for the observed loss of these cells upon
CLL progression. Nevertheless, additional factors, such as immuno-
suppression or impaired costimulation delivered by CLL cells9 may
also contribute to iNKT cell hyporesponsiveness in patients with
progressive disease, similar to T-cell exhaustion in CLL patients.37
We faced the intriguing situation in which an intact iNKT cell
response correlated with low or absent CD1d expression by CLL
cells in patients with stable disease. This suggested that iNKT cells
might also hinder CLL progression independently of CD1d cognate
recognition of leukemia cells. It has been demonstrated that
iNKT cells can indirectly control neuroblastoma or melanoma via
CD1d-dependent killing of TAMs16 or modulation of suppressive
myeloidcells,56 respectively. Indeed,we show thata-GalCer preloaded
mouse CLL cells that do or do not express CD1d were equally
controlled when injected into wt mice, suggesting that CD1d
expression by leukemia cells is dispensable for iNKT cell control.
Moreover, we provide evidence that human iNKT cells can control
CLL survival indirectly by restraining in vitro proleukemia functions
of NLCs, a CLL-specific TAM population5,8 capable of supporting
leukemia within protective niches of lymphoid tissues. Indeed, we
identified CD681 macrophage-like NLCs expressing CD1d in CLL
lymph nodes from patients with progressive disease. Our results are
relevant in light of recentfindings that support a critical pathogenic role
for macrophages in CLL. For instance, loss of macrophage migration
inhibitory factor, responsible for NLC recruitment, delays CLL de-
velopment in TCL1-tg/Mif2/2 mice,57 whereas the therapeutic tar-
geting of NLCs leads to decreased leukemia progression in preclinical
models of mouse and human CLL.11
In linewith thebiological results supporting the roleof iNKTcells in
CLL control, our multivariable analysis identified iNKT cell frequency
as an independent parameter that significantly predicts disease pro-
gression in associationwith CD38 expression. Further validation of the
prognostic power of iNKT cell frequency is needed in an independent
cohort of CLL patients.
On thebasis of the above considerations,we can envisage aunifying
model for the iNKT cell immune surveillance of CLL, whereby
the control of NLCs remains active in the long term in patients with
stable CD1dneg/low CLL, indirectly hindering leukemia progression.
By contrast, iNKT cell immune surveillance becomes impaired in pa-
tients with progressive CD1dhigh CLL, owing to the persistent antigen
stimulation of iNKT cells that ultimately leads to their functional
exhaustion and has an impact on their NLC control (Figure 6).
In conclusion, this study supports a role for the iNKT cell/CD1d
axis in the control of CLL and highlights iNKT cells as new possible
prognostic markers for disease progression.
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